about
Alternative initiation and splicing in dicer gene expression in human breast cellsVIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNAInhibition of dengue virus entry and multiplication into monocytes using RNA interferenceCell-based microarrays: current progress, future prospects.Global down-regulation of gene expression in the brain using RNA interference, with emphasis on monoamine transporters and GPCRs: implications for target characterization in psychiatric and neurological disorders.Silencing herpes simplex virus type 1 capsid protein encoding genes by siRNA: a promising antiviral therapeutic approach.Functional delivery of siRNA in mice using dendriworms.The polyamidoamine-mediated inhibition of bcl-2 by small hairpin RNA to induce apoptosis in human lens epithelial cells.RNA interference mediated inhibition of dengue virus multiplication and entry in HepG2 cellsIn silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.Silencing of HIV-1 gag gene from epidemic strains among men who have sex with men (MSM) in Tianjin, China by a broad-spectrum short hairpin RNA.Efficient inhibition of intraperitoneal ovarian cancer growth in nude mice by liposomal delivery of short hairpin RNA against STAT3.Multiple shRNA combinations for near-complete coverage of all HIV-1 strainsRNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivoIn silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1.Tumor-targeted drug delivery with aptamersA concise peer into the background, initial thoughts and practices of human gene therapy.Time depended Bcl-2 inhibition might be useful for a targeted drug therapy.Pharmacogenomics and therapeutic prospects in Alzheimer's disease.RNA interference for treating haematological malignancies.The silent treatment: siRNAs as small molecule drugs.Antiviral applications of RNAi for coronavirus.Therapeutic short hairpin RNA expression in the liver: viral targets and vectors.Silencing neurodegenerative disease: bringing RNA interference to the clinic.Potential antivirals and antiviral strategies against SARS coronavirus infections.SiRNA-mediated reduction of alpha-actinin-1 inhibits pressure-induced murine tumor cell wound implantation and enhances tumor-free survivalDrug discovery and delivery in the 21st century.MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapyReversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro96 shRNAs designed for maximal coverage of HIV-1 variants.Social Ecology, Genomics, and African American Health: A Nonlinear Dynamical PerspectiveNew drugs for hepatitis C virus.Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success.Targeted RNA interference for hepatic fibrosis.Study on the Biological Characteristics of CD133 (+) Cells Interfered by RNA Interference in Gastric Cancer.Application of RNA interference in treating human diseases.Emerging options in the treatment of dyslipidemias: a bright future?RNAi-mediated gene silencing in cancer therapy.siRNA: a new approach to target neuropathic pain.
P2860
Q24531192-AEEB77DA-0C39-432B-964C-82AEFA3F3186Q24621942-C33ADF75-86E1-41D0-BB78-EBB1806CEC98Q28478179-8E8E22AF-DC20-4898-BDF2-3A062B4E8B10Q33218861-DDDA5934-1EE7-451F-9F0D-393199F02884Q33264255-F576667C-0D47-480B-BD52-D254FEFA4AC1Q33560548-A9CCC020-D027-41E0-984A-B0613A7B843AQ33686651-B3E08AB9-3CDC-4145-85F2-B4B61600EE5DQ34134038-8487BF15-7D8C-4359-9333-970E02A2E36CQ34212157-C3B39155-4727-4497-B5FB-F88209259FE0Q34221633-DBEAE277-D635-4570-B61C-F51CA500C044Q34300106-D99E299D-3C3D-468A-8987-AECDABBC9859Q34419534-72BFC263-C684-4346-9885-78EF0066EFF7Q34552467-3539DD55-A93B-4E43-BA52-D95DFDB5546CQ35225270-53C94E6A-C505-4A9C-BF4D-3754601D5BC1Q35310313-A4225DF2-105B-458B-98AA-E035DB2E459AQ35490874-CB4A7991-4C61-4022-9699-AA8EF46D5DB0Q36098953-C22E7061-EC56-4FFF-852C-C6F7FDB3FCD4Q36243019-5C564059-23F9-496F-92F7-86A3AFEFE591Q36273420-14F8329B-F54D-4B84-94FF-A5B1E477E60AQ36327055-6173A7A7-0FA8-4359-812D-F3EBF3DC0532Q36362370-03D29E57-01DF-4A38-BAEE-C5FA2877EDF7Q36376425-32FB68C0-9012-4FC8-AB1C-DAD664313860Q36384459-B7691916-606E-4BF9-AA2D-EF9CB322761BQ36390831-94C33D22-7E8A-467A-B46F-DCD759BED9B5Q36441511-BE5BBBDF-7F98-43BF-B963-6E008E6ECA91Q36485279-3310DE29-78F1-4DF2-B26C-61FAABCF90D8Q36678920-A2B45F05-3081-4EFB-AD73-F6D99FD31A4DQ36709542-E76BC687-74E7-4BE7-B4CA-B38322A861A4Q36782324-72CC89E0-76A1-4BCD-9A80-EA4B5C7E6789Q37122329-0C6CE08F-491A-4F5A-88CF-0C9237BF359AQ37233732-9ADA1E96-BA74-4417-804F-5A9504881C76Q37297344-4E2EF625-A454-4479-9CCA-9F93C0922C5EQ37346061-A4421D2C-7910-448A-83A9-AED786930A77Q37417692-33C406FA-BA54-4CAB-9CB3-5CE756C2E849Q37590368-9B1CC94F-B989-4CC3-A74A-367DB0268DC1Q37688113-22BEA305-DFD2-4FE2-BC29-C498F5F3E512Q37832903-28EB493E-3EA6-4E69-AE99-9137C9318540Q37842462-49E5E60A-A7C5-42FD-B324-894D089B9FC2Q38030982-B7AAF1D7-0513-4820-B850-54E77CD09EFDQ38051429-97CE2B78-7F08-4D2D-8906-5529937E04C3
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Therapeutic potential of RNA interference
@ast
Therapeutic potential of RNA interference
@en
Therapeutic potential of RNA interference
@nl
type
label
Therapeutic potential of RNA interference
@ast
Therapeutic potential of RNA interference
@en
Therapeutic potential of RNA interference
@nl
prefLabel
Therapeutic potential of RNA interference
@ast
Therapeutic potential of RNA interference
@en
Therapeutic potential of RNA interference
@nl
P356
P1476
Therapeutic potential of RNA interference
@en
P2093
Mario Stevenson
P304
P356
10.1056/NEJMRA045004
P407
P577
2004-10-21T00:00:00Z